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The proteasome is responsible for the majority of
protein degradation within eukaryotic cells and pro-
teasome inhibitors have gained blockbuster status
as anticancer drugs. Here, we introduce an analytical
platform comprising reverse phase chromatography,
intact protein mass spectrometry, and customized
data analysis that allows a streamlined investigation
of proteasome integrity and posttranslational modifi-
cations. We report the complete mass spectrometric
assignment of all subunits of the yeast core particle,
as well as of the human constitutive 20S proteasome
and the human immunoproteasome, including phos-
phorylated isoforms of a7. Importantly, we found
several batches of commercially available immuno-
proteasome to also contain constitutive catalytic
subunits. Moreover, we applied the method to study
the binding mechanisms of proteasome inhibitors,
both validating the approach and providing a direct
readout of subunit preferences complementary to
biochemical methods. Collectively, our platform fa-
cilitates an easy, reliable and comprehensive detec-
tion of different types of covalent modifications on
multisubunit protein complexes with high accuracy.
The controlled degradation of proteins is of pivotal importance
for cellular proteostasis. In eukaryotic cells, the proteasome is
responsible for the majority of protein breakdown in both cytosol
and nucleus (Hershko and Ciechanover, 1998; Kisselev and
Goldberg, 2001; Voges et al., 1999). The 20S proteasomal core
particle (CP) is composed of four seven-membered rings that
are stacked corresponding to an a7:b7:b7:a7 stoichiometry (Fig-
ure 1A) (Groll et al., 1997; Lowe et al., 1995). Among all subunits,
only b1c, b2c, and b5c are catalytically active. During an inflam-
matory state, they can be exchanged with alternative b1i, b2i,
and b5i subunits to form the immunoproteasome (Huber et al.,
2012; Unno et al., 2002). Every single catalytic subunit has its
distinct cleavage site preference (Nussbaum et al., 1998) but
they all share the general architecture as threonine protease,
which gives rise to a number of intricate inhibition mechanisms
by covalent inhibitors (Dubiella et al., 2014; Groll et al., 2000).404 Chemistry & Biology 22, 404–411, March 19, 2015 ª2015 ElsevieBoth the constitutive proteasome (cCP) as well as the immuno-
proteasome (iCP) are attractive drug targets for the treatment
of cancer and autoimmune diseases, respectively.
Serine/threonine phosphorylation, N-terminal truncation, and
N-terminal acetylation are the most common posttranslational
modifications of the 20S proteasome (Lu et al., 2008; Utten-
weiler-Joseph et al., 2008). Sample heterogeneity has become
apparent from 2D gel electrophoresis due to multiple isoforms
and has been analyzed via proteolytic digests with peptide-based
massspectrometry (HuangandBurlingame,2005).While routinely
feasible, this approach is characterized by several working steps
and incomplete sequence coverage (Claverol et al., 2002; Wang
et al., 2007). Intact protein mass spectrometry (IPMS) has been
applied to proteasomes that have identical a and b subunits
(Looet al., 2005;Sharonet al., 2007). Approaches to studyeukary-
otic proteasomes by IPMS have been complicated by sample
complexity and have thus been hampered by incomplete
coverage as well as limited applicability (Dechavanne et al.,
2013; Groll et al., 1999; Russell et al., 2013). MALDI-TOF analysis
after 2Dgel separationallowed the identificationofall subunits (Ut-
tenweiler-Joseph et al., 2008), however some isoforms could not
be resolved (Bousquet-Dubouch et al., 2011). Most recently, a
top-down analysis (Loo et al., 1990) with several fragmentation
methodsonahigh-endFourier transform-ioncyclotron resonance
(FT-ICR) spectrometer allowed the investigation of cCP and its
modifications after reverse phase separation (Lakshmanan et al.,
2014). In this approach, spectra had to be selected manually for
processing and a simulated gel view was used for plotting the re-
sults. This procedure illustrates a common challenge with com-
plex samples for IPMS, since these samples typically consist of
more species than there are peaks in the total ion current chro-
matogram. This not only makes the detection of all species by
manual selectionof spectra challengingbut alsoprevents a robust
and comprehensive assessment of sample properties. Here, we
introduce an easy to implement and broadly applicable platform
with automated software that enables comprehensive IPMS
analysis of proteasome integrity, function, and inhibition.
We first validated the sample complexity by obtaining high-
resolution mass spectra from online desalted yeast 20S protea-
some (yCP) on an FT-ICR spectrometer. As anticipated, the
deconvoluted data were of poor quality due to large spectral
crowding. We then used an optimized gradient for C4-based
reverse phase chromatography that enabled subunit separation
(Figure 1B). Taking inspiration from the literature (Durbin et al.,
2010; Lee et al., 2002; Tran et al., 2011), we devised softwarer Ltd All rights reserved
α7
α4
α5 α6
α1
α2α3
α4
β1
β7
β2
β6
β5
β4
β3
α7α5
α6
α1
α2α3
α4
A
30 35 40 45 50 55 60
21000
22000
23000
24000
25000
26000
27000
28000
29000
30000
31000
32000
33000
m
as
s
(D
a)
retention time (min)
B
C
D
E
F
α1
α7
∗
α4 α5 α3
β3
β7
α6
β1β4
β5
β6
β2
α2
25070 25080 25090 25100
0
500
1000
1500
).u.a(
ytisnetni
mass (Da)
20000 25000 30000
0
500
1000
1500).u.a(
ytisnetni
mass (Da)
β6
β2
α7
β2
0 20 40 60 80
0
10
20
noilatot
01/tnuoc
6
yCP
31200 31400 31600 31800
0
500
1000
1500
2000
in
te
ns
ity
(a
.u
.)
mass (Da)
α7+P3
α7+P2
ΔM = 79.71 Da
M(P) = 79.98 Da
Figure 1. Analysis of Yeast Proteasome
(A) Surface representation of the yCP crystal structure (PDB ID 1RYP) in side and top view.
(B) Total ion count chromatogram of yCP separation.
(C) Map derived from rolling-window spectral deconvolution data analysis and subunit assignment. Colors depict arbitrary intensities obtained from deconvo-
lution (blue/green/yellow/orange/red, from high to low intensity). The mass of the cluster denoted with an asterisk (*) corresponds to the mass of a C terminally
truncated isoform of a7 (residues 2-273 with acylation and triple phosphorylation; expected mass: 30,191.4 Da; mass found: 30,190.5 Da).
(D) Deconvoluted spectrum showing the presence of subunit b2 (retention time window, 34.5–35.9 min).
(E) Mass determination of b2 through Gauss fitting (Mexpected = 25,085.44 Da, Mfound = 25,085.26 Da).
(F) Deconvoluted spectrum showing the 2-fold and 3-fold phosphorylated isoforms of subunit a7 (retention time window, 32.8–34.5 min). See also Figure S1 and
Table S1.for a rolling-window spectral deconvolution analysis (RoWinPro).
In this automated analysis, sequential sets of scans (windows)
covering the entire run are averaged and deconvoluted indivi-
dually. RoWinPro is able to handlemultiple jobs, e.g. for the anal-
ysis of several data sets or of one data set with different param-Table 1. Mass Spectrometric Assignment of the Yeast Proteasome
Subunit Gene Name Uniprot ID Sequencea Acb
a1 PRS2 P21243 2–252 +
a2 PRE8 P23639 2–250 +
a3 PRE9 P23638 2–258 +
a4 PRE6 P40303 2–254 +
a5 PUP2 P32379 1–260 +
a6 PRE5 P40302 1–234 +
a7 PRE10 P21242 2–288 +
b1 PRE3 P38624 20–215 
b2 PUP1 P25043 30–261 
b3 PUP3 P25451 2–205 +
b4 PRE1 P22141 1–198 +
b5 PRE2 P30656 76–287 
b6 PRE7 P23724 20–241 
b7 PRE4 P30657 34–266 
aSequence denotes the first and last amino acid in the processed protein.
bAc denotes whether the subunit is acylated (+) or not (). The N-termini o
propeptides that are cleaved off autoprocessively during assembly of the p
cThe major species of a7 was found to be three-times phosphorylated.
Chemistry & Biology 22, 4eters. Its main advantage over other existing tools is its ability to
process sequential windows within one data file, thus covering
the entire chromatogram automatically. For the underlying
deconvolution step, RoWinPro utilizes the Znova algorithm as
implemented in the commercially available software PromassSubunits
Expected
Mass (Da)
Mass Found
with Xtract (Da) D (Da)
Mass Found
with Znova (Da)
27,911.65 27,911.28 0.4 27,911.7
27,072.66 27,072.60 0.1 27,071.7
28,625.04 28,624.22 0.8 28,624.5
28,349.89 28,349.12 0.8 28,350.1
28,659.11 28,658.04 1.1 28,658.5
25,646.01 25,645.87 0.1 25,645.4
31,686.90c 31,686.15 0.7 31,686.3
21,494.18 21,493.79 0.4 21,493.9
25,085.44 25,085.26 0.2 25,084.4
22,515.68 22,515.16 0.5 22,514.9
22,558.68 22,558.33 0.4 22,557.7
23,300.25 23,299.86 0.4 23,299.4
24,850.88 24,850.75 0.1 24,850.1
25,919.51 25,920.19 0.7 25,919.6
f b1, b2, b5, b6, and b7 are protected against N-terminal acetylation by
roteasome (Groll et al., 1999).
04–411, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 405
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Figure 2. Maps Derived from Rolling-Window Spectral Deconvolution Data Analysis
(A–D) Human constitutive proteasome (cCP, A), immunoproteasome (iCP) sample 1 (B), sample 2 (C), and sample 3 (D).
Selected partially degraded/alternatively processed or missing subunits are highlighted with dashed boxes. See also Figure S2, Figure S3, and Table S2.(Zhang and Marshall, 1998). However, any deconvolution pro-
gram that features a command-line-based interface can be im-
plemented. In order to visualize the results, a sample map can
be constructed by plotting detected protein masses over the
mean retention times of the analyzed scans. We then subjected
these data to intensity-weighted k-means clustering. Clusters on
the yCP sample map could be assigned to all 14 subunits of the
proteasome with distinct posttranslational modifications (phos-
phorylation, truncation, and acetylation), in agreement with an-
notations in the Uniprot database (Figure 1C; Table 1). We then
selected spectra with maximal intensity for each subunit and
performed high accuracy mass determination using deconvolu-
tion with the Xtract algorithm and Gauss fitting (Figure S1). Such
analysis enabled us to obtain high-quality spectra in isotopic res-
olution of the b2 subunit that had so far been elusive to mass
spectrometry (Groll et al., 1999) (Figures 1D and 1E). While no in-
tensity was observed for the mass anticipated for subunit a7, we
obtained two clusters that were heavier by +160 Da and +240 Da
and were thus assigned to 2-fold and 3-fold phosphorylated iso-
forms, respectively (Figure 1F). For all other subunits, no such
clusters corresponding to phosphorylated isoforms were found.
We determined the stoichiometry of these isoforms through de-
convolution with four different algorithms, which gave similar re-
sults. 82.5% ± 2.2% (mean ± SD) of the a7 signal was derived
from the 3-fold phosphorylated isoform while correspondingly
17.5% ± 2.2% was derived from the 2-fold phosphorylated iso-406 Chemistry & Biology 22, 404–411, March 19, 2015 ª2015 Elsevieform (Table S1). a7 phosphorylation at Ser258, Ser263, and
Ser264 was previously identified by proteomic experiments
(Soufi et al., 2009). Here, we report that a7 phosphorylation is
the only major phosphorylation observed in yCP. Our data on
the protein level thus complement proteomic data with the quan-
titative phosphorylation stoichiometry, which can be difficult to
obtain through peptide-based methods (Carpy et al., 2014).
Next, we turned to the human constitutive proteasome and to
the human immunoproteasome and subjected them to a similar
analysis (Figure 2; Figure S2). Our analytical platform allowed for
the complete assignment of all subunits with mass accuracies
<1 Da (Table 2; Figure S2). Monophosphorylation represented
the dominant modification of a7 while all other subunits were
only detected as unphosphorylated isoforms. This finding is in
agreement with previous results (Lakshmanan et al., 2014; Olsen
et al., 2010; Zong et al., 2008). The degree of a7 monophosphor-
ylationwas determined highly reproducibly and robustly from ten
independent samples and three different cCP batches to be
95.7% ± 1.1% (mean ± SD, Table S2). a7 phosphorylation has
been implicated with an increased 20S-19S interaction (Bose
et al., 2004). While the maps of the cCP samples were generally
of high quality (Figure 2A), the data derived from three different
batches of commercially obtained iCP showed a higher degree
of heterogeneity. Importantly, all three iCP samples contained
substantial amounts of the respective constitutive subunits,
partly as the only detectable catalytic species (as for b2c andr Ltd All rights reserved
Table 2. Mass Spectrometric Assignment of the Human Constitutive Proteasome and the Human Immunoproteasome Subunits
Subunit Gene Name Uniprot ID Sequence Ac
Expected
Mass (Da)
Mass Found
with Xtract (Da) D (Da)
Mass Found
with Znova (Da)
a1 PSMA6 P60900 2–246 + 27,310.27 27,309.60 0.7 27,309.6
a2 PSMA2 P25787 2–234 + 25,809.38 25,809.14 0.3 25,808.8
a3 PSMA4 P25789 2–261 + 29,394.61 29,394.28 0.4 29,393.9
a4 PSMA7 O14818 2–248 + 27,797.64 27,797.69 0.0 27,797.5
a5 PSMA5 P28066 1–241 + 26,453.04 26,452.53 0.5 26,452.9
a6 PSMA1 P25786 1–263 + 29,597.60 29,597.07 0.6 29,596.7
a7 PSMA3 P25788 2–255 + 28,424.04a 28,423.57 0.5 28,423.8
b1c PSMB6 P28072 35–239  21,903.87 21,903.29 0.6 21,903.2
b2c PSMB7 Q99436 44–277  25,294.97 25,294.44 0.6 25,294.3
b3 PSMB3 P49720 2–205 + 22,859.74 22,859.47 0.3 22,859.7
b4 PSMB2 P49721 1–201 + 22,878.28 22,877.76 0.6 22,878.2
b5c PSMB5 P28074 60–263  22,458.34 22,457.87 0.5 22,457.8
b6 PSMB1 P20618 29–241  23,548.94 23,548.32 0.7 23,547.9
b7 PSMB4 P28070 46–264  24,391.75 24,391.21 0.6 24,391.5
b1i PSMB9 P28065 21–219  21,276.02 21,275.45 0.6 21,275.2
b2i PSMB10 P40306 40–273  24,648.25b 24,630.75/24,647.47 0.8 24,630.3/24,647.5
b5i PSMB8 P28062 73–276  22,659.60 22,659.61 0.0 22,659.4
Subunits are numbered according to their homology to the respective yeast counterparts. Of note, different numbering schemes are present in the
literature (Dechavanne et al., 2013). Localization of cCP subunit modifications through top-down analysis has been reported recently by Lakshmanan
et al. (2014).
aa7 was found to be monophosphorylated.
bThe majority of b2i appeared as a lighter isoform (17 Da) in all samples; only a weak signal for the canonical b2i was detected.b5c in iCP sample 2, Figure 2C) while in sample 3 (Figure 2D) the
catalytic b1i subunit was apparently missing. Whereas mouse
immunoproteasome can be purified from mouse liver after iCP
enrichment through viral infection, human iCP is typically purified
from cells that express both the constitutive and immunoprotea-
some-specific subunits, likely explaining these results. In addi-
tion, the existence of intermediary-type proteasomes with a
mixed composition of catalytic subunits has been reported
(Bousquet-Dubouch et al., 2011). We detected additional clus-
ters shifted to lower masses with regard to the parent noncata-
lytic subunits which were assigned to N-terminal truncation
products (marked in dashed boxes). In some cases, the full-
length isoform was completely missing (as a6 in sample 3, Fig-
ure 2D) or had become a minor species (as a4 in sample 2, Fig-
ure 2C). Unexpectedly, the b2i subunit appeared as an isoform in
all samples as themajor species that was17 Da lighter than the
canonical sequence would suggest. This mass difference would
be consistent with an Asn/ Pro or with a Met/ Asn mutation
(more complicated patterns of mutations are possible as well;
however, the precise determination of themass difference is pre-
cluded by the presence of multiple oxidized species). Of note,
variants corresponding to point mutations as a result of SNPs
have been described for other subunits (Uttenweiler-Joseph
et al., 2008). While our analysis cannot match the localization
precision of peptide-based methods, it provides insights into
sample integrity that are difficult to obtain from conventional pro-
teomic approaches. All observed alterations might have impor-
tant consequences for structural integrity and catalytic activity
of the proteasome. Mass spectrometry (MS)-based subunit
mapping can assess this heterogeneity (Claverol et al., 2002)Chemistry & Biology 22, 4and variance in different samples beyond the capabilities of 2D
gel electrophoresis, and we believe this heterogeneity has to
be considered when discussing results derived from such immu-
noproteasome batches. We also established the analysis on a
common low-resolution ion-trap mass spectrometer (Figure S3),
ensuring a broad applicability of the method.
Clinically applied proteasome inhibitors such as bortezomib
(Velcade) and carfilzomib (Kyprolis) have gained blockbuster
status as anticancer drugs (Huber et al., 2012; Kisselev and
Goldberg, 2001). Moreover, immunoproteasome-specific in-
hibitors are currently being developed by both industrial and
academic groups with promising results against diseases char-
acterized by aberrant immune function (Basler et al., 2014).
Different statements have been made in the literature regarding
the combination of subunits that needs to be inactivated to
evoke cytotoxicity, although b5c/b5i are generally assumed
to be the most important targets. Several techniques exist to
assess subunit specificity of proteasome inhibitors. Fluorogenic
substrates are widely used, however, results are at times ques-
tioned because of cross-reactivity with other proteases or similar
substrate preferences (e.g. b5c and b1i). Moreover, subunit-spe-
cific activity-based probes exist (Li et al., 2014); however, their
readout by gel fluorescence imaging restricts its use for the anal-
ysis of catalytic subunits and does not inform about inhibition
mechanisms. Crystallography was recently applied for this pur-
pose (Stein et al., 2014) but, despite the detailed insights, its
low throughput and restriction to well-crystallizable forms of
the proteasome limit its application (Dubiella et al., 2014).
We reasoned that our approach might be complementing
these techniques for covalent inhibitors and we consequently04–411, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 407
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Figure 3. Analysis of Human cCP Treated with 25 mM Carfilzomib
(A–D) (A) Structure of carfilzomib and overlay of maps from untreated cCP (gray) and carfilzomib-treated cCP (color). Shifts of the catalytic subunits are indicated
in boxes. Deconvoluted spectra showing the b1c (B), b2c (C), and b5c (D) subunits (upper panels, untreated cCP; lower panels, treated cCP).
(E) Gauss-fitting analysis of b5c spectral data confirming the mass of the carfilzomib adduct.
See also Figure S4.applied our analytical platform to the investigation of subunit
specificity and inhibitor mechanisms. First, we analyzed the
effects of the well-characterized, irreversibly binding inhibitor
carfilzomib on the catalytic subunits of cCP (Harshbarger et al.,
2015; Huber et al., 2015) (Figure 3A). Overlay of the deconvolu-
tion maps clearly showed the disappearance of the clusters rep-
resenting unmodified b2c and b5c subunits while nearby new
clusters appeared; other subunits remained unchanged. We
then selected spectra for Xtract deconvolution and found that
these new clusters correspond to masses of b2c:carfilzomib
and b5c:carfilzomib adducts (Figures 3B–3E). A minor cluster
with a b1c:carfilzomib adduct was identified, which is in agree-
ment with incomplete binding as evident from the deconvolution
spectra (Figure 3B). When treated with a lower concentration
(2.5 mM, see Figure S4B), modification of only b5c was observed,
which is in line with the published b5c selectivity. Furthermore,
we analyzed samples of cCP incubated with MG-132 and a vinyl
sulfone-based inhibitor (Figures S4C–S4E), all consistently
showing b5c-modified species. Notably, due to the protein con-
centration in the sample (0.5mg/ml, corresponding to 1.4 mMper
catalytic subunit), this analysis cannot be used to infer com-
pound potencies as these are usually in the nanomolar range.
However, a competition experiment with several covalent inhib-
itors present in the reaction can be used for a relative compari-
son of compound potencies.
Collectively, the platform reported herein facilitates a fast, reli-
able, and comprehensive evaluation of different proteasome
samples (Figure 4). We have recently applied this method to
the study of short-lived species and novel chemical modifica-
tions, demonstrating its capacity to contribute to the investiga-408 Chemistry & Biology 22, 404–411, March 19, 2015 ª2015 Elsevietion of inhibitor bindingmechanisms (Dubiella et al., 2014). More-
over, it opens the possibility of screening for covalent binders
of noncatalytic subunits. Its capabilities greatly surpass 2D gel
electrophoresis andwe therefore expect it to be useful for quality
control and sample characterization purposes. In addition, the
platform can be used to compare proteasome samples derived
from cells with different genomic backgrounds in order to assist
in the investigation of proteasome assembly, subunit process-
ing, and regulation through posttranslational modifications.
Compiled versions and documentation of the rolling-window
deconvolution analysis program are available for download at
http://www.oc2.ch.tum.de free of charge.
SIGNIFICANCE
IPMS is a powerful tool that can inform about protein com-
plex integrity and the stoichiometry of posttranslational
modification, two properties that are difficult to obtain
through peptide-based mass spectrometric methods. How-
ever, there are typically more species than peaks in the total
ion current chromatogram in complex samples, which
makes the detection of all species by manual selection of
spectra challenging. Here, we introduce a program that fa-
cilitates an automated, comprehensive data analysis, and
creates data for an intuitive visualization of the results in
the form of a sample map. We apply this analysis technique
to the investigation of several proteasome samples, vali-
dating the approach, proving its complementarity to existing
methods, and showing its usefulness in protein biochem-
istry and chemical biology research.r Ltd All rights reserved
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Figure 4. Schematic Depiction of the Work-
flow.EXPERIMENTAL PROCEDURES
Sample Preparation
Yeast proteasome was freshly purified from Saccharomyces cerevisiae as
described previously (Groll et al., 2006). Human constitutive proteasome and
human immunoproteasome were obtained from Boston Biochem. Inhibitors
were either purchased from Selleckchem or synthesized as described previ-
ously (Stein et al., 2014). Proteasome solution (0.5 mg/ml) in 50 mM HEPES
(pH 7.6), 100 mM NaCl, 1 mM DTT (for cCP and iCP) in 20 mM MES (pH
6.8), 150 mM NaCl (for yCP) was incubated with indicated inhibitor concentra-
tions for 12 hr at room temperature and then brought to 30% (v/v) acetonitrile.
Reverse Phase Chromatography and IPMS
Analyses were carried out on a Dionex UltiMate 3000 high-performance liquid
chromatography (HPLC) system coupled to a Thermo Scientific LTQ-FT UltraChemistry & Biology 22, 404–411, March 19, 2015mass spectrometer with an electrospray ioniza-
tion (ESI) source (room temperature; ionization
voltage, 3.9 kV; tube lens, 110 V; capillary voltage,
20 V; sheath gas, auxiliary gas, and sweep gas,
off). A heated ESI source could also be used
(vaporizer temperature, 70C; ionization voltage,
4.45 kV; tube lens, 120 V; capillary voltage, 30 V;
sheath gas, 30 arb; auxiliary gas, 10 arb; sweep
gas, off), demonstrating the broad applicability
and transferability of the method. Eluent A con-
sisted of water with 0.1% formic acid, eluent B
consisted either of 90% acetonitrile and 10% wa-
ter with 0.1% formic acid or 100% acetonitrile with
0.1% formic acid. All solvents were of liquid chro-
matography LC/MS grade (Sigma-Aldrich). Sam-
ples (10 ml, corresponding to 4.7 pmol/3.5 mg of
proteasome per run) were separated on a C4 col-
umn (BioBasic-4, Thermo Scientific, 150 mm 3
1 mm, 5 mm; flow, 0.050 ml/min) with a gradient
from 30% to 60% B over 60 min preceded by a
15 min equilibration step at 30% B and followed
by a washing step at 100% B for 5 min. The
mass spectrometer was run in positive mode, col-
lecting full scans at high resolution (R = 200,000)
from m/z 500 to m/z 2,000. For the low-resolution
experiment, the sample was analyzed on a Dionex
UltiMate 3000 HPLC system coupled to a Thermo
Scientific LCQ Fleet mass spectrometer with a
heated ESI source (source temperature, 39C;
ionization voltage, 4.45 kV; tube lens, 90 V; capil-
lary voltage, 31 V; sheath gas, 30 arb; auxiliary
gas, 10 arb; sweep gas, off). Eluent A consisted
of water with 0.1% formic acid, eluent B consisted
of 100% acetonitrile with 0.1% formic acid. All sol-
vents were of LC/MS grade (Sigma-Aldrich). The
sample was separated on a C4 column (Bio-
Basic-4, Thermo Scientific, 150 mm 3 1 mm,
5 mm; flow, 0.050 ml/min) with a gradient from
30% to 60% B over 60 min proceeded by a
15 min equilibration step at 30% B and followed
by a washing step at 100% B for 5 min. The
mass spectrometer was run in positive mode col-
lecting ion-trap scans at scan rate ‘‘normal’’ from
m/z 300 to m/z 2,000.
Data Analysis
Xcalibur raw files were processed using custom-
ized software (RoWinPro, available for downloadat http://www.oc2.ch.tum.de) with rolling-window deconvolution analysis.
The software uses the Xcalibur developer kit (XDK) to retrieve and average
scans (window size, 10 scans for high-resolution data, 40 scans for low-reso-
lution data; parameters can be specified in a graphical user interface) and an-
alyzes them with the Znova deconvolution algorithm as implemented in the
commercially available software Promass from Novatia, LLC (Zhang and
Marshall, 1998) (input, 600–1,600 m/z; output, 18,000–36,000 Da; 1 Da mass
step size; peak width, 3; merge width, 0.3; minimum score, 2; S/N threshold, 2;
smooth width, 7; number of smooths, 2). Output files contain a list of detected
species (retention time in minutes, mass in Daltons, intensity in arbitrary units)
and were plotted with Microcal OriginPro 9.1 with a cut-off at 80% of the
summed intensity (usually corresponding to the top 10%–50% of all data
points) to reduce noise. The color scale was set to arbitrary values in order
to fully cover the intensity range of the analyzed sample. Spectra containing
subunits of interest were subsequently averaged with Xcalibur and analyzedª2015 Elsevier Ltd All rights reserved 409
by Thermo Scientific Xtract (Senko et al., 1995) for deconvolution and quanti-
fication. Gauss fits of deconvoluted Xtract spectra were carried out withMicro-
cal OriginPro. MagTran (Zhang and Marshall, 1998) and Mann’s Algorithm
(Mann et al., 1989) (as implemented in MagTran) were used to confirm decon-
volution results. Intensity-weighted k-means clustering (initial clusters, 20) was
carried out with OriginPro and MATLAB. Cluster centers were plotted as
crosses. See Figure 4 for a visual depiction of the workflow and the User Guide
available online for further details on the analysis software.
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